CymaBay Therapeutics Inc
What’s Been Dragging Down CymaBay Therapeutics Stock
CymaBay Therapeutics (CBAY) closed at $6.17 on June 12, 1.98% higher than its previous close, 28.01% above its 52-week low of $4.82, and 58.87% below its 52-week high of $15.
CymaBay Rose 127% on Positive NASH Trial Update
On Tuesday, CymaBay Therapeutics (NASDAQ:CBAY) stock rose 127.2% after the company highlighted a positive NASH trial update.
Point72 Asset Management opens new position in Pier 1 Imports
E-commerce represented approximately 1% of total sales in fiscal 2013, 4% in fiscal year 2014, 9% in the first quarter of fiscal 2015, and 9.7% in the second quarter of fiscal 2015.
Point72 Asset Management raises stake in Lumber Liquidators
The company “saw improvement in net sales trends over the course of the quarter as inventory levels recovered and the fall flooring season began.” But the shares are down 49% in the year to date.
Point72 Asset Management takes position in CymaBay Therapeutics
CymaBay Therapeutics is a clinical-stage biopharmaceutical company formerly known as Metabolex. It develops therapies to treat metabolic and rare diseases with high unmet need.
Point72 Asset Management adds position in Applied Genetic Tech
Using the company’s partnerships and experience in ophthalmology, it plans to expand into a disease indication with a larger market. The company says it expects to place a new product candidate for this large market opportunity into development some time in 2015.
CymaBay Therapeutics: What Investors Should Watch For
CymaBay Therapeutics (CBAY) is currently enrolling patients in its Phase 3 registrational trial, ENHANCE, to evaluate the use of its investigational PPARδ (peroxisome proliferator-activated receptor delta) agonist, seladelpar, in PBC (primary biliary cholangitis).
What Analysts Recommend for CBAY and VKTX
This year, CymaBay Therapeutics (CBAY) has fallen 21.60% and Viking Therapeutics (VKTX) has risen 4.31%. While both clinical-stage companies focus on advancing their nonalcoholic steatohepatitis research and development programs, Viking seems to be ahead, considering its successful Phase 2 trials.
CymaBay Therapeutics Stock Crashes Over 50%: Is It Viable?
June 11 turned out to be a terrible day for US biopharmaceutical company CymaBay Therapeutics’ (CBAY) investors.
Why Achaogen Stock Fell Steeply Yesterday
Yesterday, Achaogen (AKAO) announced that the FDA had approved its antibacterial agent, Zemdri (plazomicin), for adults suffering from complicated urinary tract infections (or cUTI) who don’t have significant treatment options.
How Analysts View BioMarin Pharmaceuticals and Peers in April
Of the 23 analysts covering BioMarin Pharmaceuticals in April 2018, eight analysts gave the stock a “strong buy” rating.
Cash Flows and Valuation Metrics of BioMarin Pharmaceuticals
BioMarin Pharmaceuticals’ (BMRN) cash, cash equivalents, and investments increased from $1.3 billion in fiscal 2016 to $1.7 billion in fiscal 2017.
Exploring CymaBay’s Other Promising Product Candidates
CymaBay Therapeutics’ (CBAY) second product candidate, arhalofenate, is being developed for the treatment of gout.